Abstract
Results from clinical trials suggest that antiarrhythmic drugs (AD) can facilitate electrical cardioversion (EC) for persistent atrial fibrillation (AF) (duration >48 hours, no spontaneous termination) by suppression of immediate reinitiation of AF following the procedure. Class IC agents may increase the atrial defibrillation threshold (DFT) by significantly reducing the availability of Na+-channel for depolarization. In contrast, class III agents may decrease the atrial DFT by markedly prolonging atrial refractoriness. Among all AD, ibutilide and amoidarone have been shown to be most effective in enhancing the acute outcome of EC.
In patients who are over 65 years of age at high risks of stroke (e.g., atherosclerotic cardiovascular disease, diabetes, hypertension, previous thromboembolism, etc.), the rhythm control strategy offers no survival advantage over the rate control strategy and frequently subjects patients to serious adverse effects of AD therapy. It can not be overemphasized that adequate anticoagulation (INR 2.0–3.0) with warfarin is needed regardless of whichever strategy is chosen unless there are contraindications. On the other hand, in patients who are under 65 years of age without structural heart disease or other risk factors of stroke, rhythm control can be the treatment of choice. Specifically, if a patient has failed EC alone or if the patient has characteristics (e.g., duration of AF >6 months, left atrium >50 mm, etc.) that EC could fail, AD may be given before the procedure to facilitate EC. In the subgroup of patients who are symptomatic with hypertrophic cardiomyopathy and severe diastolic dysfunction requiring maintenance of sinus rhythm to have sufficient ventricular function for optimization of cardiac output, an aggressive approach for rhythm control with amiodarone along with adequate anticoagulation with warfarin should be encouraged.
Similar content being viewed by others
References
Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-base cohort: The Framingham Heart Study. JAMA 1994;271:840-844.
Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: Restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996;125:311-323.
Van Gelder IC, Crijns HJGM, Lie KI. Characteristics of patients with chronic atrial fibrillation and the prediction of successful DC electrical cardioversion. In: Kingma JH, Van Hemel NM, Lie KI, eds. Atrial Fibrillation: A Treatable Disease? Amsterdam: Kluwer Academic Publishers, 1992:67-86.
Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999;340:1849-1854.
Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-936.
Sopher SM, Camm AJ. Atrial fibrillation. Maintenance of sinus rhythm versus rate control. Am J Cardiol 1996;77:24A-37A.
Marcus GM, Sung RJ. Antiarrhythmic agents in facilitating electrical cardioversion of atrial fibrillation and promoting maintenance of sinus rhythm. Cardiology 2001;95:1-8.
Van Noord T, Van Gelder IC, Crijns HJFM. How to enhance acute outcome of electrical cardioversion by drug therapy: Importance of immediate reinitiation of atrial fibrillation. J Cardiovasc Electrophysiol 2002;13:822-825.
Rossi M, Lown B. The use of quinidine in cardioversion. Am J Cardiol 1967;17:234-238.
Tse HF, Lau CP, Ayers GM. Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol. Heart 1999;82:319-324.
Vaugh Williams EM. Subgroups of class I antiarrhythmic drugs. Eur Heart J 1984;5:96-98.
Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial. Acta Med Scand Suppl 1981;645:23-28.
Jacobs LO, Andrews TC, Pederson DN, Donovan DJ. Effect of intravenous procainamide on direct-current cardioversion of atrial fibrillation. Am J Cardiol 1998;82:241-242.
Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M. Effect of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo controlled study. J AmColl Cardiol 1996;28:700-706.
Van Gelder IC, Crijns HJGM, Van Gilst WH, De Langen CDJ, VanWijk LM, Lie KI. Effects of flecainide on the atrial fibrillation threshold. Am J Cardiol 1989;63:112-114.
Lai LP, Lin JL, Lien WP, Tseng YZ, Huang SK. Intravenous sotalol decreases transthoracic cardioversion energy requirement for chornic atrial fibrillation in humans: Assessment of the electrophysiological effects by biatrial basket electrodes. J Am Coll Cardiol 2000;35:1434-1441.
Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:66-73.
Tieleman RG, Van Gelder IC, Crijns HJGM, De Kam PJ, Van Den Berg MP, Haaksma J, Van DerWoude HJ, Allessie M. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria? JAmColl Cardiol 1998;31:167-173.
De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F, Gasparini M, De Matteis C, Rotunno R, Di Napoli T. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-814.
Daoud EG, Hummel JD, Augostini R, Williams S, Kalbfleisch SJ. Effect of verapamil on immediate recurrence of atrial fibrillation. J Cardiovasc Electrophysiol 2000;11:1231-1237.
Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. N Engl J Med 2002;347:1825-1833.
Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans JM, Tissen JGP, Crijns JGM for the Rate Control versus Electrical Cardioveron for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840.
Hohnloser SH, Kuck K, Lillenthal, for the PIAF Investigators. Rhythm or rate control in atrial fibrillationpharmacological intervention in atrial fibrillation (PIAF): A randomized trial. Lancet 2000;356:1789-1794.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sung, R.J. Facilitating Electrical Cardioversion of Persistant Atrial Fibrillation by Antiarrhythmic Drugs: Update on Clinical Trial Results. Card Electrophysiol Rev 7, 300–303 (2003). https://doi.org/10.1023/B:CEPR.0000012401.72234.cd
Issue Date:
DOI: https://doi.org/10.1023/B:CEPR.0000012401.72234.cd